London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Weren't the Fool saying buy just before they tanked?
Are they hinting at sell now they have fallen out of bed?
On that basis..??
does not seem that positive to me! 02. Nov 18 Buy Manvinder Banga Individual 31. Oct 18 31. Oct 18 471 £15.26 £7,188
02. Nov 18 Buy Vivienne Cox Individual 31. Oct 18 31. Oct 18 348 £15.26 £5,312
02. Nov 18 Buy Philip Hampton Individual 31. Oct 18 31. Oct 18 2,867 £15.26 £43,750
02. Nov 18 Buy Urs Rohner Individual 31. Oct 18 31. Oct 18 471 £15.26 £7,188
08. Aug 18 Sell Claire Thomas Individual 07. Aug 18 07. Aug 18 -40,000 £15.95 £-637,848
25. Jul 18 Buy Manvinder Banga Individual 25. Jul 18 25. Jul 18 462 £15.57 £7,188
25. Jul 18 Buy Vivienne Cox Individual 25. Jul 18 25. Jul 18 341 £15.57 £5,312
25. Jul 18 Buy Philip Hampton Individual 25. Jul 18 25. Jul 18 2,810 £15.57 £43,750
25. Jul 18 Buy Urs Rohner Individual 25. Jul 18 25. Jul 18 462 £15.57 £7,188
15. May 18 Sell Philip Thomson Individual 15. May 18 15. May 18 -65,000 £14.70 £-955,285
07. Feb 18 Buy Manvinder Banga Individual 07. Feb 18 07. Feb 18 2,250 £12.78 £28,750
20. Feb 18 Sell Patrick J. Vallance Individual 16. Feb 18 16. Feb 18 -73,783 £11.57 £-853,833
18. Dec 17 Sell Patrick J. Vallance Individual 18. Dec 17 18. Dec 17 -52,974 £13.10 £-693,754
07. Feb 18 Buy Philip Hampton Individual 07. Feb 18 07. Feb 18 3,423 £12.78 £43,750
20. Feb 18 Sell Claire Thomas Individual 16. Feb 18 16. Feb 18 -35,473 £11.57 £-410,501
07. Feb 18 Buy Vivienne Cox Individual 07. Feb 18 07. Feb 18 416 £12.78 £5,313
20. Feb 18 Sell Philip Thomson Individual 16. Feb 18 16. Feb 18 -20,524 £11.57 £-237,508
07. Feb 18 Buy Roy Anderson Individual 07. Feb 18 07. Feb 18 562 £12.78 £7,187
20. Feb 18 Sell Emma Walmsley Individual 16. Feb 18 16. Feb 18 -65,247 £11.57 ????? £-755,053
07. Feb 18 Buy Urs Rohner Individual 07. Feb 18 07. Feb 18 562 £12.78 £7,188
Making a nice recovery today by the looks of it.
The 52 week mid price is 1442.6p ..currently sitting at 1443p ....I decided to jump in at 1430p to diversify a bit
.... no certainty with any share at the moment
Falling continue today!
yesterday was a bull trap, ..the bulls buying off the bottom only for the bears to sell into that rise today ...
Investors working out the value of expected future earnings based on :
" Adjusted EPS growth at CER for the period 2016-2020 to be at the bottom end of the mid to high single digit percentage CAGR range."
" GSK expects the acquisition of TESARO and associated R&D and commercial investments will impact Adjusted EPS for the first two years by mid to high single digit percentages, reducing thereafter with the acquisition expected to start to be accretive to Adjusted EPS by 2022."
... CAGR - Compound Annual Growth Rate...key word being "compound"
2017 - Adjusted earnings per share 111p with dividend 80p ...the company is struggling to grow ...so this aquisition is a purchase to invest over the next 2 years in the hope it will bring growth
So..I would guess some investors are leaving GSK and may not return for the moment
Can anybody please tell me the reason for falling today. Yesterday I thought it was settled the dust and it was getting up but today it seems completely different!
Yes exetrchief, the price tag banded about was between 3.5 & 4.2 Billion, amuses me that a few dodgy financial hacks with online calculators reckon that Emma has been done - always let the female negotiate when you know what you will pay. Not meant as sexist, but always know where you stand.
Don't know about buying anymore though - I think my divi portfolio may pay better, albeit for a bit more risk, with a plus 12% payer at a good price? Cant see GSK putting on a 20% capital increase in the next year or so.
Rightly or wrongly, sold 25% of holding @ 1635 - so will place elsewhere. G/L
Hi Dinoken, it seems the ''Change: -110.60 (-6.82%)'' that we can see above in our screens is wrong, it might refer to yesterday, not today.
GSK was indeed steady today, taken fron the London Stock Exchange official site:
Price (GBX) 1,511.00
Var % (+/-) +0.87% (Up +13.00)
$5 1 billion is what GSK have agreed for the purchase of Tesaro.Said to be approx £ 4 billion,with the US $ coming under increased pressure, is it likely the purchase price could end up more like £.3.5 billion or less?
Since when has a 7% drop been steady ? Same bearing as yesterday on my chart ...
I expected further falls today but the sp holds positive despite being a bad day for the markets. Changed my mind and bought a few hundred shares back in case the SP holds these levels, then we can see a lot higher. GLA
buying a company that will improve there chances of beating cancer has got to be good for all of us, in fact the whole
world as it seems to be on the rise posabble down to what we eat and pollution
so good luck emma and your team from one share holder
Not sure I get this overall. The Witty regime exits the oncology market by selling the lot to Novartis for $16bn back in 2014. Four years later the new CEO re-enters the fray by buying a company with a lead oncology product in direct competition with others (mainly AZN in the UK at least) and the market deems that they have overpaid for the new assets? I for one am slightly confused.
From Delaware, odd corporate laws there, heaven sent for lawyers
They are lawyers, that's what they do. In their sleep, too.
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.:Do you own shares of TESARO, Inc. (NASDAQ GS: TSRO)?Did you purchase any of your shares prior to December 3, 2018?Do you think the proposed buyout is fair?Do you want to discuss your rights?Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of TESARO, Inc. (“TESARO” or the “Company”) (NASDAQ GS: TSRO) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by GlaxoSmithKline plc (“GSK”) (NYSE: GSK) in a transaction valued at approximately $5.1 billion. Under the terms of the agreement, shareholders of TESARO will receive $75.00 in cash for each share of TESARO common stock.If you own common stock of TESARO and purchased any shares before December 3, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.Attorney advertising. Prior results do not guarantee a similar outcome.View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005939/en/Rigrodsky & Long, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242(302) 295-5310Fax: (302) email@example.com://www.rigrodskylong.comSource: Rigrodsky & Long, P.A.
Market thinks they paid over the odds for a high risk company. Only time will tell
UNILEVER BUYS HORLICKS PLUS FROM GSK FOR ROUGHLY £3.1bn CASH AND SHARES IN
THEN GSK AGREES TO BUY US -BASED PHARMACEUTICAL GROUP TESARO FOR AROUND £4.6bn
end of the day the sp had dropped 7.62% down 123p ref HL
GOOGLE FINANCE 16.41 GSK 1503.69 AT 16.41 hrs
SO WHY THE BIG DROP TO ME THE NEWS LOOKS GOOD
and of course on the 30/11/18 https://www.fool.co.uk/i...are-price-for-christmas/
Whilst it has fallen nearly 8% today...I think some of that "higher price" was a share that was overbought before it sold off
I cant help but think the share rose ...having seen as a defensive share in a market that has been somewhat volatile..
I am sure some of the sell off has been to jump back into "more risky" shares given the pause in the trade war with China... I mean..it was 1621p on Friday and had risen too fast, too soon ..in my opinion
I think you've made a valid Point here.....
It hurts when you were looking at a healthy blue gain this morning to a less than healthy red loss thus evening. Let's hope my last purchase doesn't prove to be a vengeance trade
The Directors must be excited and positive about these recent deals, as looking at the directors buys you will see they have all recently been buying bundles of shares. Had there been plenty of sells, then you need to be worried. Lets wait and see before everyone jumps ship. Possibly and good time to top up, and 8% drop is excessive, this is what you would expect from an AIM share, not a blue chip 100.
Grayling look at US minnow for other opportunitoes, US Code below